LUND, Sweden, July 5, 2022 /PRNewswire/ -- Immunovia AB (NASDAQ
Stockholm: IMMNOV) announced, that Immunovia, Inc., its American
subsidiary, has recently received approval for a Current Procedural
Terminology (CPT) Proprietary Laboratory Analyses (PLA) code from
the American Medical Association (AMA) for the IMMray™ PanCan-d
test. The code will be effective on October
1, 2022. Immunovia is currently in process with the Centers
of Medicare & Medicaid Services (CMS) to establish payment for
IMMray™ PanCan-d with this PLA code which will be included in the
2023 CMS Clinical Lab Fee Schedule.
"We are very pleased that the AMA has approved a unique CPT PLA
code for our IMMray™ PanCan-d test. This is an important step in
our ongoing efforts to secure reimbursement for our test," says
Philipp Mathieu, CEO and President
of Immunovia AB.
The CPT codes offer doctors and health care professionals a
uniform language for coding medical services and procedures. It is
the most widely accepted medical nomenclature used in the US to
report physician and healthcare professional services including
laboratory tests under public and private health insurance
PLA Codes are an addition to the CPT code set approved by the
AMA CPT Editorial Panel. They are alpha-numeric CPT codes with a
corresponding descriptor for laboratories or manufacturers that
want to identify their test more specifically.
For more information, please contact:
CEO and President
Senior Director Investor Relations and Corporate Communications
Tel: +46 736 36 35 74
The information was submitted for publication on July 5, 2022, 9:30 am
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download: